Milestones :: Perspectives :: Research
Gavi and Japanese growth equity fund collaborate to support innovative startups for immunisation
:: Vaccine Alliance launches US$ 7.4 billion fundraising drive to deliver highest return on investment to date offering broad protection against 18 diseases, saving up to eight million lives from 2021-25
:: Developing countries set to make largest investment in their own vaccine programmes in history, more than doubling the amount invested in the 2016-2020 period
:: Sustained investment needed to secure prosperity for the next generation, prevent resurgence of diseases and protect from frequent outbreaks made worse by climate change, urbanisation and conflicts
Yokohama, 28 August 2019 – Gavi, the Vaccine Alliance and Asia Africa Investment and Consulting (AAIC), a Japanese growth equity fund based in Singapore, have agreed to a collaboration that will help companies offering innovations to improve the delivery and availability of vaccines in developing countries. Gavi and AAIC signed the agreement at the Seventh Tokyo International Conference on African Development (TICAD), where Gavi is unveiling its 2021 to 2025 Investment Opportunity.
AAIC will provide funding of up to US$ 3 million for two years to companies that AAIC identifies through Gavi’s accelerator programme, Innovation for Uptake, Scale and Equity in Immunisation, or INFUSE. The funding from AAIC will focus on INFUSE finalists, known as Pacesetters, that are supporting early- and growth-stage health care companies operating in Africa to scale new cost-effective immunisation products and services…